SG Americas Securities LLC Invests $29,000 in Werewolf Therapeutics, Inc. (NASDAQ:HOWL)

SG Americas Securities LLC acquired a new stake in shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 13,517 shares of the company’s stock, valued at approximately $29,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Janus Henderson Group PLC acquired a new stake in shares of Werewolf Therapeutics in the first quarter valued at $10,922,000. Millennium Management LLC grew its holdings in shares of Werewolf Therapeutics by 96.4% during the 2nd quarter. Millennium Management LLC now owns 1,110,298 shares of the company’s stock valued at $2,709,000 after acquiring an additional 544,881 shares in the last quarter. Vanguard Group Inc. increased its position in Werewolf Therapeutics by 26.8% in the 1st quarter. Vanguard Group Inc. now owns 1,107,347 shares of the company’s stock worth $7,176,000 after purchasing an additional 233,909 shares during the last quarter. Acadian Asset Management LLC raised its position in Werewolf Therapeutics by 22.8% during the second quarter. Acadian Asset Management LLC now owns 212,296 shares of the company’s stock valued at $516,000 after acquiring an additional 39,413 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in Werewolf Therapeutics by 103.1% in the second quarter. Renaissance Technologies LLC now owns 171,000 shares of the company’s stock worth $417,000 after purchasing an additional 86,800 shares in the last quarter. 64.84% of the stock is currently owned by institutional investors and hedge funds.

Werewolf Therapeutics Price Performance

Shares of HOWL opened at $2.72 on Wednesday. The company’s 50-day moving average is $2.25 and its 200-day moving average is $3.19. The company has a debt-to-equity ratio of 0.24, a current ratio of 12.13 and a quick ratio of 12.13. The firm has a market capitalization of $118.20 million, a PE ratio of -2.50 and a beta of 0.45. Werewolf Therapeutics, Inc. has a fifty-two week low of $1.66 and a fifty-two week high of $8.19.

Werewolf Therapeutics (NASDAQ:HOWL) last released its earnings results on Thursday, August 8th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.05). The business had revenue of $1.14 million for the quarter, compared to the consensus estimate of $2.00 million. Werewolf Therapeutics had a negative return on equity of 48.25% and a negative net margin of 578.80%. Equities analysts forecast that Werewolf Therapeutics, Inc. will post -1.64 EPS for the current year.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of Werewolf Therapeutics in a report on Tuesday, July 2nd.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.